← Back to Search

Photosensitizer

Pulsed lighting for Corneal Atrophy

Phase 1 & 2
Waitlist Available
Led By Vishal Jhanji, MD
Research Sponsored by Vishal Jhanji
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial is testing a new way to treat corneal thinning disorders using UV light and a photosensitizer called riboflavin.

Eligible Conditions
  • Corneal Atrophy
  • Keratoconus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PXL-Platinum 330 system
Other outcome measures
Efficacy measurements by best spectacle-corrected visual acuity

Trial Design

2Treatment groups
Experimental Treatment
Group I: Pulsed lightingExperimental Treatment1 Intervention
Group II: Continuous lightingExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Vishal JhanjiLead Sponsor
1 Previous Clinical Trials
Vishal Jhanji, MDPrincipal InvestigatorUPMC Eye Center
1 Previous Clinical Trials

Media Library

Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution (Photosensitizer) Clinical Trial Eligibility Overview. Trial Name: NCT05489510 — Phase 1 & 2
Corneal Atrophy Research Study Groups: Pulsed lighting, Continuous lighting
Corneal Atrophy Clinical Trial 2023: Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution Highlights & Side Effects. Trial Name: NCT05489510 — Phase 1 & 2
Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution (Photosensitizer) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05489510 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are we still enrolling patients in this clinical trial?

"The clinical trial in question is no longer recruiting patients. The study was first posted on 1/15/2023 and the last update to the posting was 11/10/2022. Although this particular research project has completed subject recruitment, there are 54 other studies which are still actively looking for participants."

Answered by AI

Who else is applying?

What state do they live in?
North Carolina
What site did they apply to?
UPMC Eye Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
PXL-Platinum 330 in Eyes With Corneal Thinning Conditions
Vishal Jhanji 2023. "PXL-Platinum 330 in Eyes With Corneal Thinning Conditions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05489510.
~0 spots leftby Dec 2031
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top